PuSH - Publication Server of Helmholtz Zentrum München: Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Wente, M.N.* ; Sauer, P.* ; Mehrabi, A.* ; Weitz, J.* ; Büchler, M.W.* ; Schmidt, J.* ; Schemmer, P.*

Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.

Clin. Transplant. 20, 80-84 (2006)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.

Impact Factor

Scopus SNIP

Altmetric

0.000